Scott Hinds

  • Citations Per Year
Learn More
In pharmaceutical R&D decision making, as in any business, the set of available options has diverse risk–return characteristics. Obviously, a random selection from this set fails to optimize the risk–return balance of an R&D portfolio, and so firms adopt various practices to achieve this goal more effectively. In this article, we propose that current(More)
  • 1